reVision Therapeutics, Inc.的封面图片
reVision Therapeutics, Inc.

reVision Therapeutics, Inc.

制药业

Ridgewood,NJ 230 位关注者

Innovative medicines to protect vision. Revising how medicines are developed and commercialized.

关于我们

Our (re)Vision: Bring impactful ophthalmic medicines to as many patients as possible as quickly as possible. The company is pursuing products that address unmet needs, can be priced for access, and still have substantial commercial potential. reVision Therapeutics, Inc. was founded in 2018 to develop medicines with high disease impact, and rapidly get those medicines to patients. The company prioritizes areas of unmet or poorly met needs in ophthalmic disorders by repurposing approved or rescuing shelved drugs that could change patients’ lives. Repurposing or rescuing drugs allows for faster development at a reduced cost. Our lead program is a product for Stargardt disease, a retinal degenerative disease that often begins in childhood. Our candidate is a repurposed, GRAS (generally recognized as safe) cyclodextrin delivered intravitreally that could work as a first-line therapy or in combination with other products currently in development. It can be developed fast and produced at a relatively low cost. Other targets include a repurposed drug for dry eye disease, a rescued therapy for proliferative vitreoretinopathy, and a combination product to treat intraocular pressure.

网站
https://revisiontx.com
所属行业
制药业
规模
2-10 人
总部
Ridgewood,NJ
类型
私人持股
创立
2018
领域
Repositioning drugs、Dry eye disease、Stargardt disease和Ophthalmology

地点

reVision Therapeutics, Inc.员工

动态

  • reVision Therapeutics, Inc.转发了

    Friends & Followers -- Happy New Year! We wish to kick off 2025 with an information session on the Resnick Prize. On?Tuesday, January 14, 12-12:30pm ET?you are invited to attend a Zoom meeting to learn about the Susan and Gene D. Resnick ’70, MD ’74 Prize for Excellence in Entrepreneurship (“Resnick Prize”).??The Resnick Prize is an annual, Cornell University-wide competition that provides?funding to startups with an active, intercampus collaboration involving Weill Cornell NYC and another campus in Ithaca, New York, or Qatar.??Startups initiated on the Weill Cornell, Ithaca, Cornell Tech, or Qatar campuses are eligible to apply?as long as?the startup has a license to Cornell-owned technology that touches Weill Cornell Medicine through either a research or clinical collaboration.?We are seeking exciting collaborations where teams can work together on a technology that will be commercialized via a startup.?The winning company will receive up to $10,000 in prize money. The Resnick Prize seeks to fund projects in all sectors (therapeutics, devices, digital health, research & AI tools,?etc) impacting healthcare and patient outcomes.?Teams must have incorporated their company to be eligible for the award.?? ? Please?RSVP to learn more about the application process and eligibility. https://lnkd.in/eY9Tm-g9 #innovation, #deepscience, #healthcare, #entrepreneurship, #nondilutivefunding

相似主页

查看职位